1. We've addressed a number of the issues raised in the previous survey. Please help us make sure we're aware of all issues by completing this new, short, confidential survey. Thank you!
  2. Need help finding a board? Read this post for help

Selling Pradaxa

Discussion in 'Boehringer Ingelheim' started by Anonymous, Mar 22, 2013 at 2:28 PM.

  1. Anonymous

    Anonymous Guest

    Canadian Rep Here. Came across some marketshare numbers in the US. Are these for real? This would suggest that a significant # of Docs have never written Pradaxa. We are having a tough time up here breaking through 10% share.

    Weekly Anticoagulant Scripts, U.S. Market Share Brand Nov. 2 2012, percent share of 821,110 scripts

    Warfarin 72.7%
    Enoxaparin 6.8%
    Pradaxa 6.6%
    Xarelto 3.5%
    Coumadin 3.1%
    Heparin 2.1%
    Brilinta 0.4%
    Lovenox 0.4%
    Others 4.4%

    Source: Barclays/IMS Health
     
  2. Anonymous

    Anonymous Guest

    That's 2011 numbers.
     
  3. Anonymous

    Anonymous Guest

    Also the lawyers here in the states have had a real big squelching of uptake. Nothing scares a doc more than a lawyer and so most don't want to mess with the hassle. They themselves don't have to take a crappy drug everyday so no big impetus to switch unless a patient begs for it.
     
  4. Anonymous

    Anonymous Guest

    This drug is done
     
  5. Anonymous

    Anonymous Guest

    Original poster here. I thought it seemed low. What would you estimate Pradaxa's marketshare to be now.
     
  6. Anonymous

    Anonymous Guest

    I would say whatever it is, it has peaked. I'm seeiing a lot of Eloquis use.
     
  7. Anonymous

    Anonymous Guest

    Clearly you aren't seeing the box that the new one comes in. You missed the spelling, hans
     
  8. Anonymous

    Anonymous Guest

    I am seeing Pradaxa go down every week. Our Cardio Rep wears an olive suit.
     
  9. Anonymous

    Anonymous Guest

    i've seen a lot of female reps go down too, what's your point
     
  10. Anonymous

    Anonymous Guest


    I call on the Chief of Cardiology at KU Med Center and hardly any one in their Department uses Pradaxa because of the potential for bleeds if a problem happens. It is a good drug if the patient doesn't have a lot of other problems and needs surgery but Coumadin would be the safer choice for the really sick patients.
     
  11. Anonymous

    Anonymous Guest

    Dude, pdax has been out over two years, no one cares what you or you stupud KU fucktards think. The days of making stupud swipes at a now old drug is utterly pointless and irretrievably stupid. Give it a rest, no one cares.
     
  12. Anonymous

    Anonymous Guest

    The market seems to care... BI sank about $2B developing Pradaxa, at this rate it won't recoup that investment. Without a share price to take the hit, it seems like is the reps whose necks are on the block for this, "dude".
     
  13. Anonymous

    Anonymous Guest

    Do you even know how much it's grossed, dipshit?
     
  14. Anonymous

    Anonymous Guest

    Original Poster. Still tyring to determine Pradaxa's current share. Came across the following from September 2012:

    "Pradaxa increased its share of the oral anticoagulant market from 3.1 percent to 18.9 percent."


    Is this correct?
     
  15. Anonymous

    Anonymous Guest

    Yeah. 3.5% of a $2.4B per year market this past year, somewhat less than that for the 2 years prior. So about $250-300M. It's not algebra, it's arithmetic.
     
  16. Anonymous

    Anonymous Guest

    Jezus you're a dolt:

    BI is a multi-national company.
    Pradaxa is an international product.

    BI is not a public company so they will never release true amount made. Since all of Europe has it free with no copays needed by patients then I'd surmise they are doing quite well.
     
  17. Anonymous

    Anonymous Guest

    Lets all sue because Pradaxa kills people. Warfarin Rules.
     
  18. Anonymous

    Anonymous Guest

    570 million in sales in USA in 2011. Over 750 million in sales in USA in 2012. Over a billion in 2 full years. Add the sales from October- Dec of 2010 and so far in 13 and that's pushing over 1.5 billion in sales since launch in USA alone. 2013 will be around 750-800 million in Sales. Not at billion per year in US yet, but still doing pretty well. Believe MKT share is around 5-6%.
     
  19. Anonymous

    Anonymous Guest

    Another vote for rat poison.
     
  20. Anonymous

    Anonymous Guest

    Original poster here.

    If 5-6% market share is correct that means that physicians still have not widely adopted Pradaxa and the only thing driving sales is the high price. Is that how the sales force would see it?
     

Share This Page